Zura Bio Limited ZURA
4.04
(0.12)
(2.88%)
as of 25 Sep
- Market cap
- $398.7M
- P/E
- 0.0×
Follow ZURA
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 4.23 | 4.23 | 0.02 | 0.12 | 4.97 | 9.16 | 9.05 |
Net Debt/EBITDA |
— | 0.67 | 0.82 | 0.01 | 0.06 | 1.59 | 3.20 | 1.45 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | (0.13) | (0.16) | (0.30) | 0.04 | 0.22 | 0.62 | 0.65 |
Capex/Depreciation |
— | — | — | — | 0.00 | 0.00 | (563.89) | (2.31) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | 11.32% | 5.70% | (58.00%) | (356.78%) | (43.38%) | (79.52%) | |
| — | 11.98% | 4.87% | 2.52% | (44.14%) | (130.52%) | (32.38%) | (67.71%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 956.66% | 778.43% | (197.75%) | 248.35% | (85.97%) | (28.49%) | (99.33%) |
Research and Development Expense of Revenue |
— | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.06) | (0.35) | (0.06) | (57.90) | (0.70) | (0.44) | (0.69) |
Cash per Share |
— | 0.04 | 0.23 | 0.00 | 6.87 | 3.02 | 2.35 | 1.16 |
Shareholders Equity per Share |
— | 7.55 | (2.93) | 7.75 | (41.91) | 1.84 | 1.98 | 1.08 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 7.55 | (2.93) | 7.75 | (41.91) | 1.84 | 1.98 | 1.08 |
Free Cash Flow |
— | (1.10) | (1.10) | (1.07) | (13.20) | (23.05) | (33.15) | (64.93) |
Working Capital |
— | 0.88 | 0.88 | (1.79) | (13.04) | 80.54 | 159.23 | 99.90 |
Capital Expenditures |
— | — | — | — | (12.00) | (8.00) | (5.07) | (0.11) |
Net Current Asset Value |
— | (9.20) | (148.58) | (7.73) | (13.04) | 60.87 | 147.57 | 99.90 |
| Other line items | ||||||||
Quick Ratio |
— | 2.68 | 2.68 | 0.01 | 0.11 | 4.92 | 9.04 | 8.82 |
Depreciation/Fixed assets |
— | — | — | — | — | — | 0.10 | 0.39 |
Cash ROIC |
— | (0.84%) | 12.99% | (0.80%) | 15.05% | (9.37%) | (8.67%) | (30.79%) |
Accounts Payable Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.06) | (0.35) | (0.06) | (5.27) | (0.46) | (0.37) | (0.69) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | (52.63) | (0.24) | (0.07) | 0.00 |
Average Payables |
— | — | — | — | 0.22 | 10.33 | 19.91 | 15.96 |
Average Assets |
— | 70.28 | 140.55 | 141.03 | 73.38 | 53.05 | 140.19 | 146.74 |
Average Common Equity |
— | — | 60.51 | 62.28 | 55.85 | 19.41 | 104.61 | 124.95 |
Capex to Sales |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates